DG

Deepak Goswami

Active Director Director DIN 07572723
DIN 07572723 First appointment Aug 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 2 historical roles
Total affiliations 6 Since Aug 2016
Shareholding value •••• Premium profile

About Deepak Goswami

Data last updated:

Deepak Goswami is a Director at Wellix Healthcare Private Limited (since 2016), Director at Mapthon Pharmaceuticals Private Limited (since 2018) and Director at Raizel Biotech Private Limited (since 2023), and holds 1 more current directorship. The companies operate in Pharma, Business Services and Paper. The 3 current companies with reported revenue have a combined latest revenue of ₹5.94 Cr; the largest is Wellix Healthcare Private Limited at ₹4.98 Cr (FY 2025). Earlier, Deepak Goswami was a Director at Optreum Pharma Private Limited (2018) and Director at Terveks Pharmaceuticals Private Limited (2020–2022).

DIN 07572723
Primary Designation Director
Industry Pharma
First Appointment 04 Aug 2016
Oldest Company Age 10 yrs
Largest company Wellix Healthcare Private Limited · ₹4.98 Cr (FY 2025)
Combined revenue ₹5.94 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Wellix Healthcare Private Limited U74999JH2016PTC009039
Director04 Aug 20162016₹4.98 Cr (FY 2025)Active
Director28 Sep 20182018₹64.3 Lakh (FY 2020)Active
Raizel Biotech Private Limited U21001CH2023PTC044941
Director19 Mar 20232023₹31.5 Lakh (FY 2025)Active
Wellix Formulation Private Limited U21000CH2024PTC045894
Director14 Sep 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Optreum Pharma Private Limited U74995JH2018PTC011524
Director15 Jun 20182018₹23.2 Lakh (FY 2021)Active
Director19 Feb 20202020₹5.1 Lakh (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Raizel Biotech Private Limited
Wellix Healthcare Private Limited
Mapthon Pharmaceuticals Private Limited
Wellix Formulation Private Limited
Premium access

Shareholding and investment profile for Deepak Goswami

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Deepak Goswami

Deepak Goswami currently holds 4 directorships: Wellix Healthcare Private Limited (Director, since 04 Aug 2016, revenue ₹4.98 Cr (FY 2025)); Mapthon Pharmaceuticals Private Limited (Director, since 28 Sep 2018, revenue ₹64.3 Lakh (FY 2020)); Raizel Biotech Private Limited (Director, since 19 Mar 2023, revenue ₹31.5 Lakh (FY 2025)); Wellix Formulation Private Limited (Director, since 14 Sep 2024).

Deepak Goswami was first appointed on 04 Aug 2016 as Director at Wellix Healthcare Private Limited. The most recent appointment on record is 14 Sep 2024 at Wellix Formulation Private Limited.

The 3 current companies of Deepak Goswami that report revenue have a combined latest revenue of ₹5.94 Cr: Wellix Healthcare Private Limited ₹4.98 Cr (FY 2025); Mapthon Pharmaceuticals Private Limited ₹64.3 Lakh (FY 2020); Raizel Biotech Private Limited ₹31.5 Lakh (FY 2025).

Deepak Goswami held 2 earlier board appointments: Optreum Pharma Private Limited (Director, 15 Jun 2018 to 01 Dec 2018); Terveks Pharmaceuticals Private Limited (Director, 19 Feb 2020 to 15 Nov 2022).

The current boards of Deepak Goswami's companies include Bijay Kumar Goswami (Wellix Healthcare Private Limited), Amita Mishra (Mapthon Pharmaceuticals Private Limited), Sandeep Thakur (Raizel Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available